Advances in antipsychotics for pharmacotherapy have greatly benefited patients with schizophrenia by improving their psychotic symptoms and social recovery. On the other hand, the average life expectancy of patients with schizophrenia is much shorter than that of the general population by 10 years or more. Physical risks caused by their unhealthy lifestyle and side effects of antipsychotics, such as obesity and glycolipid metabolism abnormalities, are of concern. Currently, the Japanese mental health care system is being shifted from hospital-based to community-based. However, promoting discharge or community transition without sufficient health consciousness and health management will likely increase the physical risks and shorten the healthy life expectancy of these patients. Therefore, the Japan Psychiatric Hospital Association and Japanese Society of Clinical Neuropsychopharmacology launched "The Joint Project on Antipsychotic Treatment and Physical Risk" to survey the physical risks related to current antipsychotic treatment in Japan. They have also initiated educational activities. In this report, I will summarize the findings from the project and make some recommendations.
 <Author's abstract>